Xeris Biopharma Holdings (XERS) EBT Margin (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted EBT Margin of 2.69% for Q1 2026, down 79.19% on a QoQ basis from 12.91% in Q4 2025, and up 1802.0% year-over-year from 0.14% in Q1 2025.
Xeris Biopharma Holdings (XERS) EBT Margin (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' EBT Margin history runs 7 years deep, the most recent figure standing at 2.69% for Q1 2026.
- Quarterly EBT Margin rose 1802.0% year-over-year to 2.69% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3.81% (up 2523.0% YoY) and the FY2025 annual result came in at 0.19%, up 2831.0% from the prior year.
- EBT Margin was 2.69% for Q1 2026 at Xeris Biopharma Holdings, down from 12.91% in the prior quarter.
- Across five years, EBT Margin topped out at 12.91% in Q4 2025 and bottomed at 154.59% in Q1 2022.
- A 5-year average of 38.6% and a median of 30.7% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin surged 20414 bps — and 2024, when it slumped 920 bps.
- Xeris Biopharma Holdings' EBT Margin stood at 40.03% in 2022, then rose by 23 bps to 30.7% in 2023, then jumped by 72 bps to 8.51% in 2024, then soared by 252 bps to 12.91% in 2025, then plunged by 79 bps to 2.69% in 2026.
- Business Quant data shows XERS's EBT Margin at 2.69% in Q1 2026, 12.91% in Q4 2025, and 0.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.97% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 33.51% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -41.57% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.73% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 30.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.35% |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 2.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.69% |
| Dec 31, 2025 | 12.91% |
| Sep 30, 2025 | 0.83% |
| Jun 30, 2025 | -2.70% |
| Mar 31, 2025 | -15.34% |
| Dec 31, 2024 | -8.51% |
| Sep 30, 2024 | -35.13% |
| Jun 30, 2024 | -29.66% |
| Mar 31, 2024 | -45.95% |
| Dec 31, 2023 | -30.70% |
| Sep 30, 2023 | -25.93% |
| Jun 30, 2023 | -53.98% |
| Mar 31, 2023 | -50.71% |
| Dec 31, 2022 | -40.03% |
| Sep 30, 2022 | -74.58% |
| Jun 30, 2022 | -104.81% |
| Mar 31, 2022 | -154.59% |
| Dec 31, 2021 | -237.02% |
| Sep 30, 2021 | -235.16% |
| Jun 30, 2021 | -308.95% |